Blepharoplasty

RVL Pharmaceuticals plc Reports First Quarter 2023 Financial Results; Provides Commercial Update

Retrieved on: 
星期四, 五月 11, 2023
Insurance, Telehealth, Blepharoplasty, Marketing, Tax, Optometry, Prescription, GAAP, Research, Absorption, Pharmacy, Sale, Medication, Depreciation, Growth, Adjustment, Colin Markison, RVL, Pharmaceutical industry, Video game, Cryptocurrency, Bank, Bookkeeping, EBITDA

-- UPNEEQ Won “Best Eye Drop for Drooping Lids” NewBeauty in 13th Annual Beauty Awards, selected from among 10,000 entrants --

Key Points: 
  • In fact, monthly pharmacy prescriptions reached an all-time high during the first quarter of 2023, despite the absence of personal promotional support.
  • Additionally, momentum in aesthetics continued, with growth in the percentage of reorders and in new account openings during the quarter.
  • UPNEEQ net product sales were $8.8 million, an increase of $2.9 million, or 49%, over the first quarter of 2022.
  • Adjusted EBITDA loss is reconciled from net loss, the most comparable GAAP financial measure, in the attached table “RVL Pharmaceuticals plc - GAAP to Non-GAAP Reconciliations” at the end of this press release.

NVISION Announces Continued Expansion in Texas with Two New Partnerships

Retrieved on: 
星期五, 五月 5, 2023
NVISION, Partnership, Ectropion, Peel (fruit), Acquisition, MD, Patient, Ophthalmology, Growth, Stye, Photorejuvenation, Dentistry, Nursing, Blepharoplasty, Entropion

ALISO VIEJO, Calif., May 5, 2023 /PRNewswire/ -- NVISION Eye Centers, a national leader in eye care services, is pleased to announce its continued expansion in Texas with Eyeplastx and the South Texas Ambulatory Surgery Center, both located in San Antonio.

Key Points: 
  • ALISO VIEJO, Calif., May 5, 2023 /PRNewswire/ -- NVISION Eye Centers, a national leader in eye care services, is pleased to announce its continued expansion in Texas with Eyeplastx and the South Texas Ambulatory Surgery Center, both located in San Antonio.
  • The South Texas Ambulatory Surgery Center provides the latest surgical treatments for ophthalmology patients.
  • "We are thrilled to partner with Eyeplastx and the South Texas Ambulatory Surgery Center," said Chris Karkenny, CEO of NVISION.
  • "This acquisition is an important step in our continued growth and expansion of services throughout San Antonio.

RVL Pharmaceuticals plc to Discuss First Quarter 2023 Financial Results and Provide Commercial Update

Retrieved on: 
星期四, 五月 4, 2023
Blood pressure, Glaucoma, Blepharoplasty, Ptosis, Orthostatic hypotension, Hypotension, Focal neurologic signs, Stroke, Cardiovascular disease, Eye, Orbit, Myasthenia gravis, Beta blocker, Hypertension, Telecanthus, Ophthalmoparesis, Metabolism, Patient, Xanthine oxidase inhibitor, Risk, Eye injury, Glycosidic bond, System, Aneurysm, Headache, Horner's syndrome, Phosphorus, Pharmaceutical industry

Ptosis may be associated with neurologic or orbital diseases such as stroke and/or cerebral aneurysm, Horner syndrome, myasthenia gravis, external ophthalmoplegia, orbital infection and orbital masses.

Key Points: 
  • Ptosis may be associated with neurologic or orbital diseases such as stroke and/or cerebral aneurysm, Horner syndrome, myasthenia gravis, external ophthalmoplegia, orbital infection and orbital masses.
  • Consideration should be given to these conditions in the presence of ptosis with decreased levator muscle function and/or other neurologic signs.
  • Advise UPNEEQ patients with cardiovascular disease, orthostatic hypotension, and/or uncontrolled hypertension or hypotension to seek medical care if their condition worsens.
  • Caution is advised in patients taking monoamine oxidase inhibitors which can affect the metabolism and uptake of circulating amines.

Shah Plastic Surgery Expands with New Premises and Procedures

Retrieved on: 
星期五, 三月 31, 2023
Mayo Clinic, Filler (linguistics), Breast augmentation, Suite, Abdominoplasty, Blepharoplasty, Growth, Clinical professor, Mastopexy, Dentistry, Rhinoplasty

Shah Plastic Surgery officially opened its doors in March 2018 and began offering a range of surgical and non-surgical treatments.

Key Points: 
  • Shah Plastic Surgery officially opened its doors in March 2018 and began offering a range of surgical and non-surgical treatments.
  • The opening of the new surgery has come with new treatments, which include scarless closed rhinoplasty, TruFlex (rapid muscle sculpting), and migraine surgery.
  • Introducing the new treatments proves an exciting development for Shah Plastic Surgery.
  • Shah's accolades, the expansion of his flagship surgery, and the diversification of procedures speak to further potential growth in the future.

RVL Pharmaceuticals Announces that Upneeq® Wins “Best Eye Drop for Drooping Lids” NewBeauty in 13th Annual Beauty Awards

Retrieved on: 
星期一, 四月 3, 2023
Blood pressure, Heart, Pressure, Blepharoplasty, Bureau of Oceans and International Environmental and Scientific Affairs, Marketing, Stroke, Ptosis, Eye, GameChanger, Myasthenia gravis, Brain, Prostate, Aneurysm, Doctor of Philosophy, Hypertension, Telecanthus, Beauty, Eyelid, Patient, Xanthine oxidase inhibitor, Risk, Nature, Annual report, Eye injury, Security (finance), Cover My Eyes (Pain and Heaven), Dry, FDA, Headache, Glaucoma, Safety, Mouth, Horner's syndrome, Pharmaceutical industry, Telescopic sight, Medical device, Veterinary medicine, Nursing, Oxymetazoline

BRIDGEWATER, N.J., April 03, 2023 (GLOBE NEWSWIRE) --  RVL Pharmaceuticals plc (Nasdaq: RVLP) (“RVL” or the “Company”) announced today that its prescription eye drop Upneeq® (oxymetazoline hydrochloride ophthalmic solution), 0.1% has been selected the winner in the professional treatment category as “Best Eye Drop for Drooping Lids” in the NewBeauty 13th Annual Beauty Awards.

Key Points: 
  • BRIDGEWATER, N.J., April 03, 2023 (GLOBE NEWSWIRE) --  RVL Pharmaceuticals plc (Nasdaq: RVLP) (“RVL” or the “Company”) announced today that its prescription eye drop Upneeq® (oxymetazoline hydrochloride ophthalmic solution), 0.1% has been selected the winner in the professional treatment category as “Best Eye Drop for Drooping Lids” in the NewBeauty 13th Annual Beauty Awards.
  • The 13th Annual NewBeauty Awards issue hits newsstands on April 4, 2023.
  • First-in-class, Upneeq® is a safe and effective, fast acting, daily treatment for patients at eye care and medical aesthetic practices nationally.
  • The most common adverse reactions with Upneeq (occurring in 1-5% of patients) were eye inflammation, eye redness, dry eye, blurred vision, eye pain at time of use, eye irritation, and headache.

Global Blepharoplasty Market to 2028: Rising Incidence of Eye-related Disorders Drives Growth - ResearchAndMarkets.com

Retrieved on: 
星期三, 四月 12, 2023
Health, Optical, Growth, Blepharoplasty, Projection, Elasticity, Incidence, Myopathy, Surgeon, Scar, Eyelid, Prevalence, Patient, Skin, Cosmetics, Health insurance

As a result, the market will be driven by rising demand for the blepharoplasty operation throughout the study period due to the increasing prevalence of these illnesses.

Key Points: 
  • As a result, the market will be driven by rising demand for the blepharoplasty operation throughout the study period due to the increasing prevalence of these illnesses.
  • Growth is expected to be boosted by the rising incidence of eye-related disorders, especially in the senior population.
  • In addition, the growing millennial population, rising disposable income, and rising healthcare costs are important factors in market expansion.
  • Over the projected period, it is anticipated that rising preference for minimally invasive procedures would offer significant opportunities for the worldwide blepharoplasty market.

Upneeq® Wins "Best Eye Drop for Drooping Lids" New Beauty In 13th Annual Beauty Awards

Retrieved on: 
星期五, 三月 31, 2023
Blood pressure, Heart, Pressure, Blepharoplasty, Bureau of Oceans and International Environmental and Scientific Affairs, Stroke, Ptosis, Eye, Myasthenia gravis, Brain, Prostate, Aneurysm, Doctor of Philosophy, Hypertension, Telecanthus, Beauty, Eyelid, Patient, Xanthine oxidase inhibitor, Risk, Eye injury, Cover My Eyes (Pain and Heaven), Dry, FDA, Headache, Glaucoma, Safety, Mouth, Horner's syndrome, GameChanger, Pharmaceutical industry, Telescopic sight, Medical device, Veterinary medicine, Nursing, Oxymetazoline

BRIDGEWATER, N.J., March 31, 2023 /PRNewswire-PRWeb/ -- RVL Pharmaceuticals announced today that its prescription eye drop Upneeq® (oxymetazoline hydrochloride ophthalmic solution), 0.1% has been selected the winner in the professional treatment category as "Best Eye Drop for Drooping Lids" in the NewBeauty 13th Annual Beauty Awards. Upneeq is FDA approved for the treatment of acquired blepharoptosis (droopy eyelids) in adults. It is the second consecutive win for the brand. Upneeq® was awarded the "Best Innovation" in 2022 by this definitive authority in beauty. The 13th Annual NewBeauty Awards issue hits newsstands on April 4, 2023.

Key Points: 
  • BRIDGEWATER, N.J., March 31, 2023 /PRNewswire-PRWeb/ -- RVL Pharmaceuticals announced today that its prescription eye drop Upneeq® (oxymetazoline hydrochloride ophthalmic solution), 0.1% has been selected the winner in the professional treatment category as "Best Eye Drop for Drooping Lids" in the NewBeauty 13th Annual Beauty Awards.
  • The 13th Annual NewBeauty Awards issue hits newsstands on April 4, 2023.
  • The most common adverse reactions with Upneeq (occurring in 1-5% of patients) were eye inflammation, eye redness, dry eye, blurred vision, eye pain at time of use, eye irritation, and headache.
  • The most common adverse reactions with UPNEEQ (occurring in 1-5% of patients) were eye inflammation, eye redness, dry eye, blurred vision, eye pain at time of use, eye irritation, and headache.

RVL Pharmaceuticals plc Reports Fourth Quarter and Full Year 2022 Financial Results; Provides Commercial Update

Retrieved on: 
星期一, 三月 20, 2023
Telehealth, Blepharoplasty, Marketing, Tax, GAAP, Research, Absorption, Sale, Medication, Traction, Depreciation, Growth, Adjustment, FDA, Colin Markison, RVL, Video game, Pharmaceutical industry, Bank, Cryptocurrency, Bookkeeping, EBITDA

BRIDGEWATER, N.J., March 20, 2023 (GLOBE NEWSWIRE) -- RVL Pharmaceuticals plc (Nasdaq: RVLP) (“RVL” or the “Company”), a specialty pharmaceutical company, today announced financial results and business highlights for the three months and full year ended December 31, 2022.

Key Points: 
  • Launched into the medical aesthetics market in February 2022 and ended the year with approximately 4,300 new customer practices having ordered UPNEEQ.
  • Selectively opened a telemedicine channel beginning in the third quarter of 2022.
  • On January 9, 2023, the Company announced preliminary fourth quarter and full year 2022 UPNEEQ net product sales of approximately $12.1 million and $36.5 million, respectively.
  • UPNEEQ net product sales were $9.8 million, an increase of $6.7 million, or 216%, over the fourth quarter of 2021.

CO2 Medical Laser Systems Global Market Report 2023: Growing Demand for Cosmetic Dentistry and Aesthetic Procedures Bolsters Sector - ResearchAndMarkets.com

Retrieved on: 
星期一, 三月 20, 2023
Health, Dental, Medical Devices, Dentistry, Infection, Blepharoplasty, United States National Library of Medicine, Stent, Gynaecology, US Foods, Obesity, National Centre for Infectious Diseases, Bleeding, IgG4-related ophthalmic disease, Prevalence, Diabetes, Dermatitis, Food, NCBI, Cardiovascular disease, Skin, Woman, National Center for Biotechnology Information, CVD, Polycystic ovary syndrome, USD, Heart, American Society of Plastic Surgeons, National library, Dermatology, Laser, Urology, Developed country, Application, PCOS, Ophthalmology, Oral hygiene, Conditional sentence, Growth, Region, Plastic, FDA, Neurology, CO2, World Health Organization, Medical device, Health care, Veterinary medicine, Pharmaceutical industry

The "CO2 Medical Laser Systems Market by Type, by Application, by End User, and by Region - Global Forecast to 2022-2033" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "CO2 Medical Laser Systems Market by Type, by Application, by End User, and by Region - Global Forecast to 2022-2033" report has been added to ResearchAndMarkets.com's offering.
  • Increasing healthcare spending, growing demand for cosmetic dentistry and improved aesthetic appearance, and adoption of technological advancements are other factors supporting the market growth.
  • The number of CVD-related preventive and therapeutic procedures has increased recently, which has boosted demand for CO2 laser cutting equipment.
  • In 2022, North America region accounted for the highest revenue in the CO2 medical laser market during the forecast period.

RVL Pharmaceuticals plc to Discuss Fourth Quarter and Full Year 2022 Financial Results and Provide Commercial Update

Retrieved on: 
星期三, 三月 15, 2023
Ophthalmoparesis, Conference, Myasthenia gravis, Hypotension, Glaucoma, Eye, International, Patient, Blood pressure, Horner's syndrome, Risk, URL, Telecanthus, Focal neurologic signs, Aneurysm, Hypertension, Metabolism, Beta blocker, Orthostatic hypotension, Ptosis, Eye injury, Glycosidic bond, Blepharoplasty, Cardiovascular disease, ID, Conference call, Headache, System, Orbit, Stroke, Xanthine oxidase inhibitor, Phosphorus, Pharmaceutical industry

UPNEEQ® (oxymetazoline hydrochloride ophthalmic solution), 0.1% is indicated for the treatment of acquired blepharoptosis in adults.

Key Points: 
  • UPNEEQ® (oxymetazoline hydrochloride ophthalmic solution), 0.1% is indicated for the treatment of acquired blepharoptosis in adults.
  • Consideration should be given to these conditions in the presence of ptosis with decreased levator muscle function and/or other neurologic signs.
  • Advise UPNEEQ patients with cardiovascular disease, orthostatic hypotension, and/or uncontrolled hypertension or hypotension to seek medical care if their condition worsens.
  • Caution is advised in patients taking monoamine oxidase inhibitors which can affect the metabolism and uptake of circulating amines.